Influence of ibuprofen-arginine on serum levels of nitric oxide metabolites in patients with chronic low back pain - A single-blind, placebo controlled pilot trial (ISRCTN18723747)

Journal of Rheumatology

Volumn 33, Issue 12, 2006, Pages 2515-2518

  Sprott, Haiko ^a   Gay, Renate E ^a   Michel, Beat A ^a   Gay, Steffen ^b  

^a Department of Rheumatology   (Switzerland)

^b Center of Experimental Rheumatology   (Switzerland)

Author keywords

Chronic pain; Ibuprofen arginine; Nitric oxide

Indexed keywords

IBUPROFEN ARGININE; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN SYNTHASE; SPEDIFEN; UNCLASSIFIED DRUG;

ADULT; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LOW BACK PAIN; MALE; METABOLITE; PAIN ASSESSMENT; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE;

ANALGESICS; ARGININE; CHRONIC DISEASE; DRUG COMBINATIONS; FEMALE; HUMANS; IBUPROFEN; LOW BACK PAIN; MALE; MIDDLE AGED; NITRIC OXIDE; PAIN MEASUREMENT; PILOT PROJECTS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33846036857     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Busson M. Update on ibuprofen: review article. J Int Med Res 1986;14:53-62.
2. Mehlisch DR, Ardia A, Pallotta T. A controlled comparative study of ibuprofen aginate versus conventional ibuprofen in the treatment of postoperative dental pain. J Clin Pharmacol 2002;42:1-8.
3. Ceppi Monti N, Gazzaniga A, Gianesello V, Stroppolo F, Lodola E. Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. Arzneimittelforschung 1992;42:556-9.
4. Sandrini G, Tassorelli C, Lanfranchi S, Nappi G. Pilot clinical trial with a new formulation of ibuprofen (ibuprofen arginine) in the treatment of migraine without aura. Funct Neurol 1994;9 Suppl 2:41.
5. Tsoukias NM, Popel AS. A model of nitric oxide capillary exchange. Microcirculation 2003;10:479-95.
6. Yan L, Vandivier RW, Suffredini AF, Danner RL. Human polymorphonuclear leukocytes lack detectable nitric oxide synthase activity. J Immunol 1994;153:1825-34.
7. Vandivier RW, Eidsath A, Banks SM, et al. Down-regulation of nitric oxide production by ibuprofen in human volunteers. J Pharmacol Exp Ther 1999;289:1398-403.
8. Jung YS, Kim DK, Kim MK, Kim HJ, Cha IH, Lee EW. Onset of analgesia and analgesic efficacy of tramadol/acetaminophen and codeine/acetaminophen/ibuprofen in acute postoperative pain: a single-center, single-dose, randomized, active-controlled, parallel-group study in a dental surgery pain model. Clin Ther 2004;26:1037-45.
9. Wallace JL, Chin BC. Inflammatory mediators in gastrointestinal defense and injury. Proc Soc Exp Biol Med 1997;214:192-203.
10. Robbins RA, Grisham MB. Nitric oxide. Int J Biochem Cell Biol 1997;29:857-60.
11. Moulton PJ. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci 1996;53:317-24.
12. Aley KO, McCarter G, Levine JD. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neuroscience 1998;18:7008-14.
13. Holthusen H, Arndt JO. Nitric oxide evokes pain in humans on intracutaneous injection. Neurosci Lett 1994;165:71-4.
14. Holthusen H, Arndt JO. Nitric oxide evokes pain at nociceptors of the paravascular tissue and veins in humans. J Physiol 1995;487:253-8.
15. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997;811:60-7.
16. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999;19:51-71.
17. Coleman JW. Nitric oxide in immunity and inflammation. Int Immunopharmacol 2001;1:1397-406.
18. Murad F. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Recent Prog Horm Res 1998;53:43-60.
19. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615.
20. Sakaue G, Shimaoka M, Fukuoka T, et al. NF-κ B decoy suppresses cytokine expression and thermal hyperalgesia in a rat neuropathic pain model. Neuroreport 2001;12:2079-84.
21. Sung CP, Arleth AJ, Shikano K, Berkowitz BA. Characterization and function of bradykinin receptors in vascular endothelial cells. J Pharmacol Exp Ther 1988;247:8-13.
22. Steranka LR, Manning DC, De Haas CJ, et al. Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci USA 1988;85:3245-9.
23. Kindgen-Milles D, Klement W, Arndt JO. The nociceptive systems of skin, paravascular tissue and hand veins of humans and their sensitivity to bradykinin. Neurosci Lett 1994;181:39-42.
24. Zhang C, Reiter C, Eiserich JP, et al. L-arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem 2001;276:27159-65.